Document is current
Any future updates will be listed below
-
Authors
Tideman, Pontus https://orcid.org/0000-0002-9620-7115
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Strandberg, Olof
Calling, Susanna
Smith, Ruben https://orcid.org/0000-0001-7147-0112
Midlöv, Patrik https://orcid.org/0000-0002-5871-8731
Verghese, Philip B. https://orcid.org/0000-0003-4793-564X
Braunstein, Joel B.
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Stomrud, Erik
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 13 March 2025
Accepted: 13 August 2025
First Online: 15 September 2025
Competing interests
: S.P. has acquired research support (for the institution) from Avid and ki elements through ADDF. In the past 2 years, he has received consultancy and/or speaker fees from Bioartic, Biogen, Esai, Eli Lilly, Novo Nordisk and Roche. R.S. has received consultancy and/or speaker fees from Lilly, Novo Nordisk, Roche and Triolab. N.M.-C. received consultancy and/or speaker fees from Biogen, Merck and Owkin. O.H. is an employee of Eli Lilly and Lund University. P.B.V. and J.B.B. are salaried employees for C2N Diagnostics and receiving compensation from the company in the form of a salary or equity. The other authors declare no competing interests.
